2012 Insight | PGEN Message Board Posts


PGEN   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  52714 of 54537  at  1/30/2023 8:07:26 PM  by

mymorningsong


 In response to msg 52707 by  Redwood1205
view thread

Re: 2012 Insight

It's a excellent point about more severe cases having better responses, but much greater data is needed for broad insurance reimbursement, especially when the goal is to create a billion dollar drug.   The reason we allow such high margins is in part because we have high regulatory barriers.   FDA won't rush this to approval when it's not life threatening and still in dose escalation.  Efficacy based on prior surgeries is good, but a somewhat flawed barometer because it is scheduled.   
 
Path forward IMO is PGEN and FDA will agree on a pivotal trial that ...
- Establishes a pre-defined approval level of surgery reduction that they will likely meet
- Bunch of sites; because why not
- Possibly randomized between DL2 and DL3; safety data too good to rush DL2 to approval
- Is there a way for this be Rare Pediatric Disease voucher eligible
  
This appears to be an approvable product.  Just not short term.  Hence the raise.   


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 1  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
52715 Re: 2012 Insight 809trader 1 1/30/2023 9:53:39 PM
52717 Re: 2012 Insight Redwood1205 0 1/30/2023 11:02:59 PM
52718 Re: 2012 Insight Mabel 0 1/30/2023 11:34:10 PM




Financial Market Data provided by
.
Loading...